Zydus Cadila receives approval for Tamsulosin capsules
Zydus Cadila has received an approval from the USFDA to market Tamsulosin capsules, 0.4 mg. Tamsulosin falls in the urology segment and is indicated for the treatment of Benign Prostatic Hyperplasia.
The FDA is amending the animal drug regulations to reflect approval of a new animal drug application filed by Intervet, Inc. The NADA provides for the veterinary prescription use of a suspension containing orbifloxacin, mometasone furoate monohydrate, and posaconazole for the treatment of otitis externa in dogs.